CAPITAL CORP. SYDNEY

73 Ocean Street, New South Wales 2000, SYDNEY

Contact Person: Callum S Ansell
E: [email protected]
P: (02) 8252 5319

WILD KEY CAPITAL

22 Guild Street, NW8 2UP,
LONDON

Contact Person: Matilda O Dunn
E: [email protected]
P: 070 8652 7276

LECHMERE CAPITAL

Genslerstraße 9, Berlin Schöneberg 10829, BERLIN

Contact Person: Thorsten S Kohl
E: [email protected]
P: 030 62 91 92

Short-term Launch Highlights on Pipeline Products Due to be Launched up to 2025

Disclaimer: The views, suggestions and opinions expressed here are the sole responsibility of the experts. No ZEX PR Wire journalist or Editor was involved in the writing and production of this article.

DUBLIN, May 12, 2020 /PRNewswire/ — The “Global Ovarian Cancer Clinical Trial Pipeline Highlights – 2020” report has been added to ResearchAndMarkets.com’s offering.

The “Ovarian Cancer Pipeline Highlights – 2020” report provides the most up-to-date information on key pipeline products in the global Ovarian Cancer market. It covers emerging therapies for Ovarian Cancer in active clinical development stages including early and late-stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:
The report provides Ovarian Cancer pipeline products by clinical trial stages including both early and late-stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:
The report provides Ovarian Cancer pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:
The report provides Ovarian Cancer pipeline products by company.

Short-term Launch Highlights:
Find out which Ovarian Cancer pipeline products will be launched in the US and beyond to 2025.

Key Topics Covered:

1. Ovarian Cancer Pipeline by Stages
2. Ovarian Cancer Phase 3 Clinical Trial Insights
3. Ovarian Cancer Phase 2 Clinical Trial Insights
4. Ovarian Cancer Phase 1 Clinical Trial Insights
5. Ovarian Cancer Preclinical Research Insights
6. Ovarian Cancer Discovery Stage Insights
7. Appendix
8. Research Methodology

List of Tables
Table 1: Ovarian Cancer Phase 3 Clinical Trials, 2020
Table 2: Ovarian Cancer Phase 2 Clinical Trials, 2020
Table 3: Ovarian Cancer Phase 1 Clinical Trials, 2020
Table 4: Ovarian Cancer Preclinical Research, 2020
Table 5: Ovarian Cancer Discovery Stage, 2020

List of Figures
Figure 1: Ovarian Cancer Pipeline Molecules by Clinical Trials Stage, 2020
Figure 2: Ovarian Cancer Phase 3 Clinical Trial Highlights, 2020
Figure 3: Ovarian Cancer Phase 2 Clinical Trial Highlights, 2020
Figure 4: Ovarian Cancer Phase 1 Clinical Trial Highlights, 2020
Figure 5: Ovarian Cancer Preclinical Research Highlights, 2020
Figure 6: Ovarian Cancer Discovery Stage Highlights, 2020

For more information about this report visit https://www.researchandmarkets.com/r/5eljq5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com